Haiping Wang

Haiping Wang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Clinical Kidney Journal
Verified
Journal Article
Open access
WSWenyan Su
Wenyan Su
JLJianyi Li
Jianyi Li
JMJinzhao Men
Jinzhao Men
SZShuo Zhong
Shuo Zhong
YWYunzhao Wang
Yunzhao Wang
HWHaiping Wang
Haiping Wang
Background: Clinical experience with obinutuzumab in patients with rituximab-refractory phospholipase A2 receptor (PLA2R)-associated membranous nephropathy remains limited. This study aimed to evaluate the efficacy and safety of obinutuzumab in treating patients with rituximab-refractory PLA2R-associated membranous nephropathy. Methods: A single-center retrospective study was conducted on 20 patients with rituximab-refractory PLA2R-associated membranous nephropathy who received two doses of 1 g obinutuzumab, administered 2 weeks apart. At 6 months, patients with urinary protein levels exceeding 3.5 g/d received an additional dose of 1–2 g obinutuzumab. The primary clinical outcome was a composite measure of complete or partial remission during follow-up. Continuous secondary outcomes included 24-hour urinary protein, serum albumin, serum creatinine, serum anti-PLA2R levels, and CD19 B-cell counts at the time of obinutuzumab infusion, at 3 months, and at the last visit. Results: A total of 20 patients with clinical manifestations of nephrotic syndrome were included in this study, with a median follow-up period of 9 months. The mean age of the patients was 46.25 ± 13.05 years. At a median follow-up of 4.50 months (3.00–8.25 months) after obinutuzumab therapy, remission was achieved in 16 patients. Two patients (10%) achieved complete remission, while 14 (70%) attained partial remission. At baseline, 16 out of 20 patients tested positive for serum anti-PLA2R antibodies, and immunological remission was observed in 11 of these 16 patients during follow-up. All patients experienced B-lymphocyte depletion within 1 month after receiving obinutuzumab infusion and maintained this depletion at 3 months. B-lymphocyte reconstitution was noted in 4 out of 20 patients (20%) at 6 months. No patients experienced fatal adverse events. Conclusion: Obinutuzumab mainly induces short-term partial remissions in patients with rituximab-refractory primary membranous nephropathy, which may be related to the short follow-up period. However, this study demonstrates that obinutuzumab is an effective and safe treatment for rituximab-refractory PLA2R-associated membranous nephropathy.

28 July 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
JLJing Lu
Jing Lu
JGJie Gao
Jie Gao
JSJing Sun
Jing Sun
HWHaiping Wang
Haiping Wang
HSHuijuan Sun
Huijuan Sun
SZShuo Zhong
Shuo Zhong
Apolipoprotein A-I (apoA-I), 90% of which is present in high-density lipoprotein (HDL), is the main constituent of HDL, has anti-inflammatory and anti-oxidant properties, and has received extensive attention in anti-atherosclerosis. Yet little is known about apoA-I ’s role in peritoneal dialysis. In this study, by analyzing PD patients (n = 81), we found that decreased apoA/HDL-C ratio is significantly associated with rapid decline in peritoneal function. Further studies were performed in animal experiments to determine the ascendancy of apolipoprotein A-I mimetic peptide (D-4F) on peritoneum, we found that D-4F administration reduced peritoneal fibrosis and peritoneal endothelial mesenchymal transformation (EMT) induced by high glucose peritoneal dialysate, such as N-cadherin, Fibronectin, Vimentin, and α-smooth muscle actin (α-SMA) expression decreased. In mechanism, D-4F can significantly inhibit Smad2/3 phosphorylation, which is the major pathway leading to fibrosis. Furthermore, D-4F treatment inhibited NADPH oxidase and thiobarbituric acid reactive substances (TBARS) expression, increased the activity of certain enzymes, such as superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px). Finally, treatment with D-4F inhibits the expression of interleukins-6(IL-6), Interleukin-1β(IL-1β), and tumor necrosis factor-α(TNF-α). Taken together, based on the above research evidence, apoA-I and its peptide mimic may regulate the oxidative stress, TGF- β1/Smads signaling pathway and inflammatory response to reduce peritoneal fibrosis due to peritoneal dialysis.

1 January 2015 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
HWHaiping Wang
Haiping Wang
ZJZhanjun Jia
Zhanjun Jia
JSJing Sun
Jing Sun
LXLiang Xu
Liang Xu
BZBing Zhao
Bing Zhao
RWRong Wang
Rong Wang
Nitrooleic acid (OA‐NO2) is an endogenous lipid product which has novel signaling properties, particularly the activation of peroxisome proliferator‐activated receptors. The current study aimed to evaluate the protective effects of OA‐NO2 against cisplatin‐induced kidney injury in mice. Mice were pretreated with OA‐NO2 for 48 h before cisplatin administration, and the cisplatin‐caused nephrotoxicity was evaluated. After the cisplatin treatment (72 h), the vehicle‐treated mice displayed renal dysfunction, as evidenced by the elevated plasma urea and creatinine, which was consistent with the histological damage, such as tubular necrosis, dilation, protein cast, and desquamation of epithelial cells. In contrast, the severity of the renal dysfunction and histological change were reduced in the OA‐NO2 pretreated mice. The renal COX‐2 and mPGES‐1 mRNAs and their respective proteins expression, together with the renal PGE2 amounts, were induced by the cisplatin treatment, but their initiation was reduced by OA‐NO2. Moreover, the circulating TNF‐α, renal TNF‐α, IL‐1β, MCP‐1, ICAM‐1, and VACAM‐1 mRNA levels were higher in the cisplatin‐treated mice, compared with the controls, but they were attenuated in the OA‐NO2 pretreatment group. In summary, the pretreatment with OA‐NO2 remarkably ameliorated the cisplatin‐induced kidney injury in mice, possibly via the inhibition of the inflammatory response, associated with the COX‐2/mPGES‐1/PGE2 cascade.

1 February 2020 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Open access
PDF file
WSWenyan Su
Wenyan Su
HWHaiping Wang
Haiping Wang
ZFZiYan Feng
ZiYan Feng
JSJing Sun
Jing Sun
As an electrophilic nitroalkene fatty acid, nitro-oleic acid (OA-NO2) exerts multiple biological effects that contribute to anti-inflammation, anti-oxidative stress and anti-apoptosis. However, little is known about the role of OA-NO2 in peritoneal fibrosis. Thus, in this study, we examined the effects of OA-NO2 on the high glucose-induced epithelial-mesenchymal transition (EMT) in human peritoneal mesothelial cells (HPMCs) and evaluated the morphological and immunohistochemical changes in a rat model of peritoneal dialysis (PD)-related peritoneal fibrosis. In an in vitro study, we found that HG reduced the expression level of E-cadherin and increased snail, N-cadherin and α-SMA expression levels in the HPMCs. The abovementioned changes were attenuated by pre-treatment with OA-NO2. Additionally, OA-NO2 also inhibited the HG-induced activation of the TGF-β1/Smads signalling pathway and the NF-κB signalling pathways. Meanwhile, OA-NO2 could inhibited the HG-induced phosphorylation of Erk and JNK. The results from the in vivo study showed that OA-NO2 notably relieved peritoneal fibrosis by decreasing the thickness of the peritoneum; it also inhibited the expression of TGF-β1, α-SMA, N-cadherin and vimentin and enhanced the expression of E-cadherin in the peritoneum. Collectively, these results suggest that OA-NO2 inhibits HG-induced EMT in HPMCs and attenuates peritoneal dialysis-related peritoneal fibrosis.

26 January 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YZYao Zhang
Yao Zhang
JSJing Sun
Jing Sun
JGJie Gao
Jie Gao
WSWeiyan Sun
Weiyan Sun
LXLiang Xu
Liang Xu
HWHaiping Wang
Haiping Wang
Rituximab (RTX) is a monoclonal antibody commonly used to treat PLA2R-associated membranous nephropathy (MN). This report presents a case of refractory MN in a patient who experienced severe hypokalemia, a rare but clinically significant condition, after the 5th RTX infusion. Clinicians should be aware of the potential for hypokalemia and its management during or after RTX infusion. After the onset of hypokalemia, the patient received treatment with obinutuzumab and achieved partial remission of renal disease without experiencing further hypokalemia. Obinutuzumab may be a viable alternative therapy for refractory membranous nephropathy that develops side effects after rituximab therapy or is refractory to it, but further studies are necessary to determine its efficacy and safety.

9 June 2015 in Experimental Biology and Medicine
Verified
Journal Article
Closed access
MYMeng Yang
Meng Yang
RWRong Wang
Rong Wang
JSJing Sun
Jing Sun
KYKezhou Yu
Kezhou Yu
BCBing Chen
Bing Chen
HWHaiping Wang
Haiping Wang
Liver X receptors are in the nuclear receptor superfamily and are contained in the regulation of lipid and cholesterol metabolism. Besides, liver X receptors are considered crucial regulators of the inflammatory response and innate immunity. The current study evaluates the in vivo effects that the synthetic liver X receptor agonist TO901317 protects against cisplatin-induced kidney injury in mice. Mice received cisplatin administration through a single intraperitoneal injection (20 mg/kg in saline). And then the mice were treated with the TO901317 by daily gavage (10 mg/kg/day) 12 h postcisplatin administration, and cisplatin nephrotoxicity was evaluated. At 72 h after cisplatin treatment, elevated plasma urea and creatinine levels ( P < 0.05) were evidenced which indicates the renal dysfunction of the vehicle-treated mice, consistent with tubular necrosis, protein cast, dilation of renal tubules, and desquamation of epithelial cells in renal tubules. In contrast, the severity of renal dysfunction and histological damage was reduced in TO901317 treated mice ( P < 0.05). In accordance, circulating tumor necrosis factor alpha levels, renal tumor necrosis factor alpha, p47phox, gp91phox, and protein expression levels and COX-2 mRNA, renal monocyte chemoattractant protein 1, VACAM-1 mRNA and intercellular adhesion molecule-1 contents, and renal prostaglandin E2 amounts, were higher in samples from cisplatin-treated mice in comparison with controls ( P < 0.05) but attenuated in the TO901317 treatment group ( P < 0.05). Taken together, treatment with the liver X receptor agonist TO901317 ameliorated the inflammatory response and oxidative stress in cisplatin-induced kidney injury in mice.